Journal of Basic and Clinical Pathophysiology

Journal of Basic and Clinical Pathophysiology

Simultaneous effect of one-month crataegus supplementation and rehabilitation program on cardiac contractile strength, blood pressure, heart rate and functional capacity of patients with heart failure

Document Type : Research Paper

Authors
Hosna Rashidi 1
Worya Tahmasebi 2
Mohsen Khalili 3
Ronak Ahmadi 4
1 Medical Physiology, School of Medicine, Shahed University, Tehran, Iran
2 Assistant Professor, Department of Sports Nutrition, Faculty of Sports Sciences, Razi University, Tehran, Iran
3 Department of Physiology, School of Medicine, Shahed University, Tehran, Iran
4 Cardiologist of Hazrat-e-Rasoul Hospital in Javanroud Assistant Professor of Pediatrics. Faculty of Medicine.Shahed University, Tehran, Iran
10.22070/jbcp.2020.5629.1134
Abstract
Background and Objective: Heart failure (HF) is one of the most prevalent and debilitating diseases of the current era, which is the leading cause of high mortality rates in human. This study aims to investigate the simultaneous effect of crataegus supplementation and a 4-week cardiac rehabilitation program on ejection fraction (EF), blood pressure (BP), heart rate (HR), and functional capacity in patients with heart failure.
Materials and Methods: 30 patients with heart failure (EF between 10 to 30%) with an average age of 50 to 75 voluntarily participated in the present study and randomly divided into three equal groups (n = 10), crataegus+exercise (cr+e), crataegus (cr), and control (c) groups. The cr+e and cr groups received the crataegus extract for one month. cr+e group did rehabilitation exercises for one month. The c group had their usual lifestyle and treatment without any regular exercise or supplement. Before and after the project, all subjects were tested for vital signs, (electrocardiogram) ECG, echocardiography, and a 6-minute walking test (6MWT).
Results: The findings showed a significant increase in EF in the cr+e group after 4 weeks (p <0.00). Results of 6MWT increased after 4 weeks in cr+e and cr groups (p <0.05) and BP and HR was improved in both groups.
Conclusion: Results indicate that 4 weeks of exercise program along with crataegus supplement will lead to the reduction of heart risk factors in patients with heart failure by increasing the contractile strength of the heart, lowering blood pressure and improving functional capacity.
Keywords
Crataegus
Rehabilitation
Ejection Fraction
  1. Azevedo A, Bettencourt P, Alvelos M, Martins E, Abreu-Lima C, Hense H-W, et al. Health-related quality of life and stages of heart failure. International Journal of Cardiology 2008;129(2):238-44.
  2. Lesman-Leegte I, Jaarsma T, Coyne JC, Hillege HL, Van Veldhuisen DJ, Sanderman R. Quality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age-and gender-matched community controls. Journal of Cardiac Failure 2009;15(1):17-23.
  3. Saleem M, Mahmud Z, Khan K. Survival Analysis of CABG Patients by Parametric Estimations In Modifiable Risk Factors-Hypertension and Diabetes. American Journal of Mathematics and Statistics 2012;2(5):120-8.
  4. Riegel B, Moser DK, Rayens MK, Carlson B, Pressler SJ, Shively M, et al. Ethnic differences in quality of life in persons with heart failure. Journal of Cardiac Failure 2008;14(1):41-7.
  5. Rector TS, Anand IS, Cohn JN. Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life. Journal of Cardiac Failure 2006;12(2):87-92.
  6. Flynn KE, Piña IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301(14):1451-9.
  7. Pires LA, Abraham WT, Young JB, Johnson KM, MIRACLE, Investigators M-I. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials. American Heart Journal 2006;151(4):837-43.
  8. Endoh M, Hori M. Acute heart failure: inotropic agents and their clinical uses. Expert Opinion on Pharmacotherapy 2006;7(16):2179-202.
  9. Bahorun T, Aumjaud E, Ramphul H, Rycha M, Luximon-Ramma A, Trotin F, et al. Phenolic constituents and antioxidant capacities of Crataegus monogyna (Hawthorn) callus extracts. Nahrung 2003;47(3):191-8.
  10. Wang J, Xiong X, Feng B. Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evidence Based Complementary and Alternative Medicine 2013;2013:149363.
  11. Cattadori G, Segurini C, Picozzi A, Padeletti L, Anzà C. Exercise and heart failure: an update. ESC Heart Failure 2018;5(2):222-32.
  12. Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA 2000;283(23):3095-101.
  13. Conraads VM, Van Craenenbroeck EM, De Maeyer C, Van Berendoncks AM, Beckers PJ, Vrints CJ. Unraveling new mechanisms of exercise intolerance in chronic heart failure. Role of exercise training. Heart Failure Reviews 2013;18(1):65-77.
  14. Dickstein K, Members ATF, Cohen‐Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008‡: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure 2008;10(10):933-89.
  15. Members WC, Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119(14):e391-e479.
  16. Hwang HS, Bleske BE, Ghannam MM, Converso K, Russell MW, Hunter JC, et al. Effects of hawthorn on cardiac remodeling and left ventricular dysfunction after 1 month of pressure overload-induced cardiac hypertrophy in rats. Cardiovascular Drugs and Therapy 2008;22(1):19.
  17. Swaminathan JK, Khan M, Mohan IK, Selvendiran K, Niranjali Devaraj S, Rivera BK, et al. Cardioprotective properties of Crataegus oxycantha extract against ischemia-reperfusion injury. Phytomedicine 2010;17(10):744-52.
  18. Abassi A, Fayyazi S, Ahmadi F, Haghighizade M. The efficacy of home walking exercise program on functional performance and quality of life in patients with heart failure. Journal of Gorgan University of Medical Sciences 2007;9(1):49-54. (in persion).
  19. Zick SM, Vautaw BM, Gillespie B, Aaronson KD. Hawthorn extract randomized blinded chronic heart failure (HERB CHF) trial. European Journal of Heart Failure 2009;11(10):990-9.
  20. Rodriguez ME, Poindexter BJ, Bick RJ, Dasgupta A. A comparison of the effects of commercially available hawthorn preparations on calcium transients of isolated cardiomyocytes. Journal of Medicinal Food 2008;11(4):680-6.
  21. Schwinger RH, Pietsch M, Frank K, Brixius K. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. Journal of Cardiovascular Pharmacology 2000;35(5):700-7.
  22. Schüssler M, Hölzl J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneimittel-Forschung 1995;45(8):842-5.
  23. Tadić VM, Dobrić S, Marković GM, Ðorđević SM, Arsić IA, Menković NaR, et al. Anti-inflammatory, gastroprotective, free-radical-scavenging, and antimicrobial activities of hawthorn berries ethanol extract. Journal of Agricultural and Food Chemistry 2008;56(17):7700-9.
  24. Roddewig C, Hensel H. Reaction of local myocardial blood flow in non-anesthetized dogs and anesthetized cats to the oral and parenteral administration of a Crateagus fraction (Oligomere procyanidines). Arzneimittel-Forschung 1977;27(7):1407-10.
  25. Karapolat H, Demir E, Bozkaya YT, Eyigor S, Nalbantgil S, Durmaz B, et al. Comparison of hospital-based versus home-based exercise training in patients with heart failure: effects on functional capacity, quality of life, psychological symptoms, and hemodynamic parameters. Clinical Research in Cardiology 2009;98(10):635-42.
  26. Asgary S, Naderi GH, Sadeghi M, Kelishadi R, Amiri M. Antihypertensive effect of Iranian Crataegus curvisepala Lind.: a randomized, double-blind study. Drugs under Experimental and Clinical Research 2004;30(5-6).
  27. Roghani M, Baluchnejadmojarad T, Dehkordi F. Discrimination of Borrelia persica and B.microiti the causative agents of relapsing fever using PCR-RFLP and specific primers. Pathobiology Research 2009;12(2):61-71 (In Persion).
  28. Machha A, Achike FI, Mustafa AM, Mustafa MR. Quercetin, a flavonoid antioxidant, modulates endothelium-derived nitric oxide bioavailability in diabetic rat aortas. Nitric Oxide 2007;16(4):442-7.
  29. Peschel W, Bohr C, Plescher A. Variability of total flavonoids in Crataegus--factor evaluation for the monitored production of industrial starting material. Fitoterapia 2008;79(1):6-20.
  30. Dianat M, Akbari G. Protective Effect of Hydroalcoholic Extract of Hawthorn Fruit on CaCl2-Induced Arrhythmias in Rat. Jundishapur Scientific Medical Journal 2014;12(6):693-703.

Journal of Basic and Clinical Pathophysiology
Volume 8, Issue 2
December 2020
Pages 28-36